Financial Consulate’s Arcutis Biotherapeutics ARQT Stock Holding History

Financial Consulate’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$106	Buy	+4	New	+$105	﹤0.01%	1805

Other funds holding ARQT

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Financial Consulate's ARQT Position: Q3 2026 in Review

Financial Consulate opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2026: 4 shares worth $106. The stake represents ﹤0.01% of the portfolio and ranks #1805 among its holdings.

43 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

Financial Consulate held 4 shares of Arcutis Biotherapeutics worth $106 as of Q3 2026.
Arcutis Biotherapeutics was a new Financial Consulate position in Q3 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1805 holding.
43 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.